CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 66 enrolled
Drug / intervention
Ialuxid geldevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05345093
NCT05345093N/ACompleted
CompareCT.gov

Open, Non-comparative, Multicentre, Interventional Clinical Investigation to Evaluate the Performance and Safety of the Medical Device Ialuxid® Gel (Hydrogen Peroxide and Hyaluronic Acid) in the Treatment of Acne Vulgaris and Folliculitis.

BMG Pharma·interventional·Posted Apr 25, 2022·Updated May 21, 2024

In Brief

A clinical study evaluating Ialuxid gel for Acne Vulgaris and Folliculitis. Completed, enrolled 66 participants across 1 site.

Detailed Summary

The Research Question of the present study is the following: in a population of men and women affected by acne vulgaris, and folliculitis, will Ialuxid® Gel (hydrogen peroxide, hyaluronic acid and glycine) improve the course of the disease, resulting in a decrease of the total number of lesions, results observed after 4 and 8 weeks after the beginning of the treatment?

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris, Folliculitis
CountriesRomania
CollaboratorsOpera CRO, a TIGERMED Group Company

Timeline

N/ACompletedFinished
2023202420252026
First PostedApr 25, 2022
Enrollment StartNov 11, 2022
Primary CompletionSep 22, 2023
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 4.2 years ago

Interventions

Ialuxid geldevice

Ialuxid® Gel is intended for topical external use. It is formulated with the appearance of white to pale yellow coloured consistent gel. Ialuxid® Gel will be used for 8 weeks, 2-3 times a day.